HERPES ZOSTER IN CHILDREN AND ADULTS: PREVENTION AND MODERN TREATMENT METHODS
Keywords:
shingles, herpes zoster, Varicella-Zoster virus, antiviral therapy, vaccination, immunity, neuropathic pain, corticosteroids, prevention, children and adults.Abstract
Shingles (Herpes Zoster) is a viral disease caused by the reactivation of the Varicella-Zoster virus (VZV), which persists in a latent state within the sensory ganglia after primary infection with chickenpox. This reactivation typically occurs when the immune system is compromised, making elderly individuals, people with chronic illnesses, and children with immunodeficiencies particularly susceptible to the disease. Clinically, shingles presents as a painful, vesicular rash localized along a dermatome, often accompanied by neurological symptoms such as burning, itching, and, in severe cases, postherpetic neuralgia. While the disease is more frequently observed in older adults, its occurrence in children, especially those with weakened immune systems, highlights the need for thorough preventive and treatment strategies. This article explores the clinical features of shingles in different age groups, emphasizing the importance of modern preventive measures, including the role of vaccination in reducing disease incidence and severity. The analysis of recent scientific studies underscores that early diagnosis and prompt antiviral therapy significantly reduce the risk of complications, such as postherpetic neuralgia, secondary bacterial infections, and neurological impairments. Furthermore, advancements in immunotherapy and the development of more effective antiviral medications have improved patient outcomes. By reviewing current treatment protocols and the latest research on shingles management, this article aims to provide a comprehensive understanding of the disease, its impact on public health, and the most effective strategies for prevention and treatment.
Downloads
References
World Health Organization (WHO). (2020). Varicella and herpes zoster vaccines: WHO position paper, June 2020. Weekly Epidemiological Record, 95(25), 265–287.
Centers for Disease Control and Prevention (CDC). (2021). Shingles (Herpes Zoster) Clinical Overview. Retrieved from www.cdc.gov
Breuer, J., Bollaerts, K., & Opstelten, W. (2020). Herpes zoster as a risk factor for stroke and TIA: A systematic review and meta-analysis. Neurology, 94(20), e2186-e2199.
Gagliardi, A. M. Z., Andriolo, B. N., Torloni, M. R., & Soares, B. G. (2021). Vaccines for preventing herpes zoster in older adults: A Cochrane review. Cochrane Database of Systematic Reviews, 2(2), CD008858.
Tricco, A. C., Zarin, W., Cardoso, R., & Nincic, V. (2021). Efficacy, safety, and immunogenicity of herpes zoster vaccines in adults aged 50 and older: A network meta-analysis of randomized controlled trials. Canadian Medical Association Journal (CMAJ), 193(9), E317-E326.
Cohen, J. I. (2020). Herpes zoster. New England Journal of Medicine, 383(24), 2260–2268.
Yawn, B. P., & Gilden, D. (2021). The global epidemiology of herpes zoster. Neurology, 97(3), S1-S6.
Harpaz, R., Leung, J., & Zhou, F. (2022). Impact of varicella vaccination on the epidemiology of herpes zoster and varicella disease. Infectious Disease Clinics of North America, 36(2), 387-401.
Curran, D., Oostvogels, L., & Heineman, T. C. (2020). Vaccine development for herpes zoster: Past, present, and future. Human Vaccines & Immunotherapeutics, 16(4), 860-869.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in the Journal of Applied Science and Social Science (JASSS) is protected by copyright. Authors retain the copyright to their work, and grant JASSS the right to publish the work under a Creative Commons Attribution License (CC BY). This license allows others to distribute, remix, adapt, and build upon the work, even commercially, as long as they credit the author(s) for the original creation.